Announced Date: 2023-11-09 (November 9, 2023)
Asset Name: ECC5004（AZD5004）
Licensor: Eccogene (China)
Licensee (Buyer): AstraZeneca（UK）
.
Asset Modality: Small Molecule, oral once-daily
Asset Target: GLP-1RA (glucagon-like peptide 1 receptor agonist)
Potential Indication: obesity, type-2 diabetes and other cardiometabolic conditions
Current Stage: Phase I clinical trial , US/China
.
Scope of Authority:
AstraZeneca is granted exclusive global rights for the development and commercialisation of Eccogene’s ECC5004 small molecule GLP-1RA for any indication in all territories except China, where Eccogene has the right to co-develop and co-commercialise in China alongside AstraZeneca.
.
Payment Detail:
Eccogene will receive:
Upfront payment of $185 million;
Clinical, regulatory, and commercial milestone payments of up to $1.825 billion;
Total up to $2.01 billion.
Tiered royalties on product net sales.
.
Link:
AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity
